Full-Time

Associate Director Scientific Communications Lead

Solid Tumors, Global Medical Affairs Oncology

Updated on 9/3/2026

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$169.4k - $266.2k/yr

+ Short-term incentives + Long-term incentives + 401(k) company match + Tuition reimbursement

Cambridge, MA, USA

Hybrid

Hybrid role based in Cambridge, Massachusetts, with up to 10% domestic and international travel.

Bachelor's, PharmD, PhD

Category
Biology & Biotech
Required Skills
SharePoint
Word/Pages/Docs
Data Analysis
Excel/Numbers/Sheets

Get referred to Takeda

See people who can refer or advise you

Requirements
  • A minimum of a Bachelor's degree in a scientific discipline plus commensurate long-term experience within the pharmaceutical or biotechnology industry, or an advanced degree in a scientific discipline.
  • At least 5 years of healthcare or related experience, including at least 3 years developing and executing medical publications within pharmaceutical or biotechnology medical affairs or a medical communications agency.
  • Knowledge of scientific publication planning processes, current good publication practice standards (GPP3), relevant external industry publication guidelines (ICMJE), and scientific reporting standards for studies (CONSORT).
  • Strong written and verbal communication skills and the ability to manage several projects simultaneously.
  • Ability to work independently and under pressure.
  • Experience with resource allocation and vendor management.
  • Ability to synthesize, interpret, present, and discuss complex medical and scientific data.
  • Understanding of pharmaceutical clinical development and product life-cycle management, clinical trial design and execution, statistical methods, and clinical trial data reporting requirements.
  • Experience in medical communications, including publications, medical information, and/or training.
  • Experience with publications management databases such as Datavision.
  • Experience working in cross-functional and global or local teams within the pharmaceutical or related industry.
  • Ability to identify opportunities and anticipate changes in the business landscape through ongoing environmental assessment.
  • Ability to cultivate organizational relationships across global, regional, and local organizations and work effectively in a matrix, cross-functional environment.
  • Ability to create a clear and unifying vision that inspires teams to excel.
  • Ability to create functional strategies and goals aligned with company objectives and develop metrics to track and assess performance.
  • Ability to contribute to data analytics and publication planning, including ideas for sub-analyses.
  • Excellent understanding of regulatory, compliance, and legal requirements.
  • Advanced personal-computer skills, including Datavision, Microsoft Project, Word, Excel, PowerPoint, and SharePoint.
Responsibilities
  • Develop, manage, and execute global or regionally integrated strategic publication and scientific communication plans in coordination with cross-functional teams and product medical strategies.
  • Initiate communication with authors, identify data required for content development, and participate in author meetings to facilitate content discussions and ensure the appropriate content development process is followed.
  • Critically review manuscripts, abstracts, posters, and oral presentations for accuracy and scientific rigor; manage and facilitate content review by collating reviewer comments and discussing them with authors and reviewers.
  • Communicate publication and scientific communications strategies, tactical plans, and progress to internal business partners; work with vendors and technical support groups to evaluate and optimize publication systems and reporting metrics.
  • Manage medical writing agencies, including oversight of publication-plan execution and budgets and maintenance of publication-management databases such as Datavision.
  • Ensure compliance with applicable laws, regulations, and policies governing the development, internal review, and dissemination of scientific communications materials.
  • Manage alliance partnerships.
  • Evaluate trends in medical publications and drive opportunities to enhance publication content and amplify publications in scientific exchange; lead or participate in process development and refinement.
  • Lead or participate in recruiting vendors to fill resource gaps.
  • Provide guidance and training to colleagues on publication-strategy development and tactical-execution best practices.
  • Coordinate, plan, and manage scientific communications budgets for assigned programs with the Global Medical Affairs Oncology Operations team.
  • Provide medical and scientific review of Global Medical Affairs Oncology materials and, when required, promotional materials, to support medical and promotional review processes.
  • Lead or contribute to content development for Global Medical Affairs projects, including NCCN compendia, training materials, global congress plans, and medical resource tools.
  • Serve as the Global Scientific Communications representative on relevant Global Medical Strategy Teams.
  • Attend conferences, symposia, or other meetings as needed or assigned and act as liaison between Global Scientific Communications and external content contributors.
Desired Qualifications
  • Oncology experience is strongly preferred.
  • An advanced degree (PhD, PharmD, or equivalent) in a scientific discipline is preferred.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Get referred to Takeda

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 FDA approval of MIMRYLO opened a new U.S. polycythemia vera franchise.
  • ORZEYFUL won U.S., Japan, and China approvals in August 2026, accelerating commercialization.
  • Takeda maintained FY2026 guidance after Q1 2026, with 22.6% growth from new launches.

What critics are saying

  • The May 18, 2026 Amitiza verdict imposed $884.9 million damages, tripling on judgment.
  • Takeda's March 2026 restructuring cuts 4,500 jobs, signaling margin pressure and execution disruption.
  • If ORZEYFUL, MIMRYLO, and zasocitinib underperform, Takeda's mature-brands decline crushes growth.

What makes Takeda unique

  • Takeda’s 2026 launches target first-in-class mechanisms: MIMRYLO, ORZEYFUL, and zasocitinib.
  • Takeda built rare Japan-to-global R&D depth, with oveporexton approved in China, U.S., Japan.
  • Takeda paired discovery teams with Boltz in 2026, embedding AI across research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 31st, 2026
Takeda wins FDA approval for first-in-class blood cancer drug, triggering $275M payment to Protagonist

The FDA approved Takeda Pharmaceutical's MIMRYLO (rusfertide) for polycythemia vera, a blood cancer causing red blood cell overproduction. The first-in-class drug functions as a hepcidin mimetic, regulating iron distribution to control hematocrit levels and prevent life-threatening complications like strokes and pulmonary embolisms. Approval was based on the Phase 3 VERIFY study involving 293 patients. Those receiving MIMRYLO alongside standard care achieved superior hematocrit control, reduced phlebotomy needs, and improved fatigue compared to placebo. Takeda commercialises MIMRYLO under a 2024 agreement with Protagonist Therapeutics, which discovered the drug. The approval triggers $275 million in payments to Protagonist—a $200 million opt-out fee plus $75 million milestone. Protagonist remains eligible for up to $875 million in additional milestones and tiered royalties of 14% to 29% on worldwide net sales.

Associated Press
Aug 28th, 2026
US FDA approves Takeda's Mimrylo for polycythemia vera treatment

Takeda has received US FDA approval for MIMRYLO (rusfertide), a first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV), a blood cancer. The drug is a hepcidin mimetic that regulates iron distribution and red blood cell overproduction to control hematocrit levels. The approval was supported by the Phase 3 VERIFY study involving 293 PV patients. Results showed MIMRYLO plus standard care demonstrated higher response rates than placebo, including better hematocrit control, reduced phlebotomy needs, and improved fatigue scores. PV affects approximately 90,000 people in the US. An estimated 78% of patients experience uncontrolled hematocrit with current standard care. The most common adverse events were injection site reactions and anaemia. MIMRYLO is administered once weekly via subcutaneous injection. Takeda is working with regulators outside the US for potential global availability.

Associated Press
Aug 24th, 2026
Japan approves Orzeyful as first medicine targeting narcolepsy type 1's underlying cause

Takeda announced Japan's Ministry of Health, Labour and Welfare has approved ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first to address the underlying orexin deficiency causing the disease, rather than just managing individual symptoms. Narcolepsy type 1 is a chronic neurological condition characterised by excessive daytime sleepiness, cataplexy, disrupted sleep, and other symptoms that significantly impact patients' daily lives. Diagnostic delays average more than 10 years. The approval follows global Phase 3 trials showing statistically significant improvements across the full range of symptoms. Common side effects included insomnia, urinary urgency and frequency, and excessive saliva. ORZEYFUL is also approved in China and the United States. Takeda developed the first-in-class orexin receptor 2 agonist in its Japanese laboratories and plans to launch the treatment quickly.

Yahoo Finance
Aug 5th, 2026
FDA approves Takeda's Orzeyful, first medicine to treat underlying cause of narcolepsy type 1

The US Food and Drug Administration has approved Takeda's ORZEYFUL (oveporexton) for treating narcolepsy type 1 in adults. The oral medication is the first orexin receptor 2 agonist approved to address the underlying cause of the disease rather than individual symptoms. Narcolepsy type 1 is a chronic neurological disease affecting approximately 120,000 people in the US. It is driven by orexin deficiency and causes excessive daytime sleepiness, cataplexy, cognitive symptoms and disrupted sleep. Clinical trials showed adults taking ORZEYFUL experienced significant improvements across the full range of symptoms compared to placebo. Takeda is preparing for the US launch, which will proceed following completion of the Drug Enforcement Administration scheduling process. The company describes the approval as potentially redefining how narcolepsy type 1 is managed.

GeekWire
Jul 31st, 2026
AI drug developer Accipiter Bio quietly tops up seed round with $10.5M

Seattle-based biotech startup Accipiter Biosciences has raised an additional $10.5 million, less than a year after emerging from stealth with $12.7 million. The funding, from existing investors including Flying Fish Partners and Takeda, will accelerate the company's drug development programmes. The startup uses AI tools developed at the University of Washington's Institute for Protein Design to engineer proteins that can bind multiple cellular targets simultaneously. The company has expanded to 22 employees, including researchers who worked under Nobel laureate David Baker. Accipiter Bio has partnerships with Pfizer and Gilead Sciences-owned Kite Pharma, with potential milestone payments exceeding $330 million. The additional funding will enable the company to advance three or four drug candidates into clinical trials, focusing on immunology and oncology.